Clinical trials
Phase 3 Meningitis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
57 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2006 | 6 |
| 2007 | 6 |
| 2008 | 4 |
| 2009 | 2 |
| 2010 | 4 |
| 2011 | 3 |
| 2012 | 4 |
| 2013 | 5 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 5 |
| 2017 | 3 |
| 2018 | 2 |
| 2020 | 2 |
| 2022 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 55 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Vaccines | 18 |
| Sanofi Pasteur, a Sanofi Company | 11 |
| GlaxoSmithKline | 10 |
| Beijing Minhai Biotechnology Co., Ltd | 2 |
| Novartis | 2 |
| Emory University | 1 |
| Hualan Biological Engineering, Inc. | 1 |
| Jiangsu Province Centers for Disease Control and Prevention | 1 |
| Johns Hopkins University | 1 |
| London School of Hygiene and Tropical Medicine | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Meningitis | 57 |
| Meningococcal Infections | 34 |
| Meningitis, Meningococcal | 19 |
| Pneumonia | 7 |
| Sepsis | 5 |
| Tetanus | 3 |
| Whooping Cough | 3 |
| Central Nervous System Diseases | 2 |
| Haemophilus Infections | 2 |
| Meningitis, Cryptococcal | 2 |
Trials
Showing 76 to 57 of 57. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.